FDA targets full approval of Pfizer COVID-19 vaccine by Labor Day: report – .

FDA targets full approval of Pfizer COVID-19 vaccine by Labor Day: report – .

The U.S. Food and Drug Administration aims to grant full approval for the Pfizer-BioNTech coronavirus vaccine by Labor Day or earlier, according to a new report.

Citing people involved in the effort, The New York Times reported on Tuesday evening that the FDA was speeding up its approval process as the country faces a new wave of infections from the more contagious delta variant.

The FDA now has an unofficial target date of early September, the Times reported. Previous speculations for full approval ranged from early fall until next January.

There has been increasing pressure on the FDA to give full approval for the vaccine, which was urgently approved last year. Some proponents of the vaccine have cited the lack of full approval as a reason for avoiding the vaccine, and it is hoped that the approval will build public confidence and encourage more people to get the vaccine.

Pfizer PFE,
requested full approval on May 7 and fellow vaccine maker Moderna Inc. MRNA,
asked the same in June.

Full approval is a much more in-depth type of authorization that takes longer; even a “priority review” can take six months. But experts have urged the FDA to speed up the process, as COVID-19 continues to spread and the vaccine has been proven to be safe and effective in millions of people.


Please enter your comment!
Please enter your name here